REGENEREX PHARMA, INC.

What they do

Regenerex Pharma develops and commercializes advanced wound care products using three proprietary technologies for chronic wound closure, acute wound acceleration, and contamination control. Its current products include Xcellderma OTC liquid bandage and Accelerex sterile wound cream, both based on the QBx active ingredient. The company has no current revenue and relies on outsourced manufacturing and strategic partnerships.

Revenue drivers

• Xcellderma OTC — Over-the-counter liquid bandage skin protectant; no revenue reported.
• Accelerex Sterile Wound Cream — First commercial medical device containing QBx for chronic and acute wounds; no revenue reported.
• Medicaid and distributor agreements — Negotiating managed care agreements with southeastern states and distributors in Asian and Middle Eastern countries; potential revenue streams exceed $100 million annually but no contracts signed.

Recent performance

The company has no revenue in fiscal years 2025 and 2024, with net losses of $2.5 million and $3.5 million respectively. Operating cash flow deteriorated from -$457,548 in 2024 to -$1.6 million in 2025. As of September 30, 2025, total assets were $617,764, total liabilities were $5.3 million, and shareholder equity was negative $4.7 million. Cash and equivalents were only $11,659.

Strategy

Management is focusing on securing Medicaid managed care agreements in southeastern states, targeting potential annual revenues exceeding $100 million. They are negotiating with private insurance networks for preferred provider status and with distributors in Asian and Middle Eastern countries. The company is also developing a proprietary AI-driven wound management system in partnership with Optimize Health Partners. Manufacturing is largely outsourced, with a lease agreement for plant and equipment in Tennessee.

Risks

• No revenue and going concern risk — The company has no revenue and negative shareholder equity, raising substantial doubt about its ability to continue as a going concern.
• Lack of operating history — Originally formed to sell artwork online, the company has limited operating history and minimal revenues in its current business.
• Competition from established players — The company faces competition from existing consumer product companies in the wound care market, which may have greater resources.
• Reliance on third-party manufacturing — Manufacturing is outsourced, and the company is undergoing FDA re-certification for drug manufacturing, creating potential supply chain and regulatory risks.

Outlook

Management expects to finalize Medicaid contracts and preferred provider agreements, which could bring significant revenue. They are also pursuing international distribution partnerships and launching the AI-driven system to differentiate their offering. However, the company's cash position is minimal, and it will need substantial funding to execute these plans.